Clinical Trials Logo

Pulmonary Hypertension Secondary clinical trials

View clinical trials related to Pulmonary Hypertension Secondary.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05993338 Enrolling by invitation - Clinical trials for Pulmonary Hypertension Secondary

Pulmonary Artery Pressure in COVID-19 Survivors

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

Post COVID-19 pulmonary hypertension can develop as a result of lung parenchymal damage and altered pulmonary circulation induced by COVID-19 infection. It has been proposed that this type of PH should be considered a combination between PH of group 3 (due to interstitial fibrosis and alveolar inflammation) and 4 (induced by thrombotic/thromboembolic processes, endothelial injury, or, at least, hypoxic vasoconstriction). Right heart catheterization (RHC) is the gold standard for assessing pulmonary hemodynamics and is mandatory for confirming the diagnosis of pulmonary hypertension (PH), assessing the severity of hemodynamic impairment, and performing vasoreactivity testing in selected patients